These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer. Patel SA, Chen MH, Loffredo M, Renshaw A, Kantoff PW, D'Amico AV. Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):234-240. PubMed ID: 28117382 [Abstract] [Full Text] [Related]
6. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer. Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M. Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883 [Abstract] [Full Text] [Related]
8. Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer. McDuff SGR, Chen MH, Renshaw AA, Loffredo MJ, Kantoff PW, D'Amico AV. Cancer; 2018 Apr 01; 124(7):1391-1399. PubMed ID: 29338073 [Abstract] [Full Text] [Related]
9. Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone. Huynh MA, Chen MH, Wu J, Braccioforte MH, Moran BJ, D'Amico AV. Int J Radiat Oncol Biol Phys; 2016 Jul 15; 95(4):1158-67. PubMed ID: 27209511 [Abstract] [Full Text] [Related]
10. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy. Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV. Int J Radiat Oncol Biol Phys; 2010 Apr 15; 76(5):1439-44. PubMed ID: 19540066 [Abstract] [Full Text] [Related]
11. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. JAMA; 2008 Jan 23; 299(3):289-95. PubMed ID: 18212313 [Abstract] [Full Text] [Related]
12. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. JAMA; 2009 Aug 26; 302(8):866-73. PubMed ID: 19706860 [Abstract] [Full Text] [Related]